This executive summary from the Investment Banking Division of DNB//Back Bay focuses on a macro environment overview of current US economic markets, policy and regulatory updates in light of the current administration’s full-spectrum overhaul of US healthcare policies and the life science ecosystems and healthcare market activity as it relates to healthcare dealmaking in the US and Europe.
Read MoreAs 2024 drew to a close, a surge of Chinese dealmaking led many industry watchers to wonder if a transformative shift in the biotech industry has begun—one that could profoundly impact the future of early-stage drug development.
Read MoreThe field of RNA biology has seen significant clinical development activity and technological advancement in recent years. Coding RNAs, in particular, act as messengers on behalf of DNA to induce expression of the more than 20,000 proteins that provide most of the structure and function in human cell biology.
Read MoreThe year 2022 was a watershed year for the radiopharmaceuticals space with 25 strategic transactions and $527M invested from the VC community. Despite an overall downturn in the biotech market in the 2022-2023 timeframe, the strategic and VC activity within the radiopharmaceutical space has remained relatively strong. Indeed, the average raise for radiopharma sponsors in 2023 was $51M, which eclipsed that of 2022, $38M.
Read MoreThe ability to facilitate the growth and expansion of mammalian cells in vitro has been at the backbone of a wave of therapeutic innovations in the biotech space. Increasingly the know-how, materials, and equipment to harness cells as factories to produce complex proteins for therapeutic uses is being directed toward consumer applications.
Read MoreA growing body of pre-clinical and clinical research has implicated the influence of bacteria on human health which over the last decade led to a flurry of venture capital and biopharma interest. The collection of non-human cells living within the gut, skin, and other tissues (collectively referred to as “microbiota” or the “microbiome”) has a profound influence on maintaining normal physiologic function (homeostasis).
Read MoreA growing body of pre-clinical and clinical research has implicated the influence of bacteria on human health which over the last decade led to a flurry of venture capital and biopharma interest. The collection of non-human cells living within the gut, skin, and other tissues (collectively referred to as “microbiota” or the “microbiome”) has a profound influence on maintaining normal physiologic function (homeostasis).
Read MoreOver the last five years, multiple gene therapies have been approved by regulatory agencies and a bolus of late-stage pipeline assets are approaching the market. As the first few gene therapies realize their potential as transformative treatments for the genetic rare diseases, the space is seen as a crucial part of growth for the biopharmaceutical industry. However, as the first gene therapies began to post early wins, several technical and commercial challenges emerged.
Read MoreOver the last decade, NASH has remained a graveyard for drug development. To date, there are no disease-specific approved therapies on the market. Companies in the dash for a NASH breakthrough may require strategic repositioning to maximize asset value in the near-term. In our latest white paper, Back Bay Life Science Advisors analyzed the opportunities and challenges ahead for companies seeking a NASH breakthrough.
Read More
